← Back to Search

Cell Therapy

PSC-01 for Osteoarthritis

Phase 1
Waitlist Available
Research Sponsored by Personalized Stem Cells, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
If a woman of childbearing potential, the study participant must not be pregnant at the time of consent and must take contraceptive measures to prevent a pregnancy while actively participating in the study
The study participant may be of any gender or ethnic background.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-4 months
Awards & highlights

Study Summary

The objective of this clinical study is to evaluate the safety of an intraarticular injection of an investigational biologic product (IBP), PSC-01, the patient's own adipose-derived stromal vascular fraction cells (SVF) extracted from a lipoaspirate sample, to treat the pain of osteoarthritis in a single knee. The secondary objective is to get initial data on efficacy of the PSC-01.

Eligible Conditions
  • Osteoarthritis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Adverse Events
Secondary outcome measures
Changes in KOOS Measurement

Trial Design

1Treatment groups
Experimental Treatment
Group I: PSC-01Experimental Treatment1 Intervention
All study participants will receive intraarticular injection of the investigational biological product, PSC-01.

Find a Location

Who is running the clinical trial?

Personalized Stem Cells, Inc.Lead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~23 spots leftby Mar 2025